6 results about "Maternal antibody" patented technology

This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind endothelin A receptor (ETAR). These ETAR antibodies, or antigen-binding fragments thereof, have a high affinity for ETAR, function to effectively block ET-1 binding to ETAR, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., in a human), and can be used to treat ETAR-associated disorders. Importantly, compared to small molecule ETAR antagonists, the antibodies of the present invention have advantages of longer serum half-life, higher target specificity, thereby limiting the risk of off-target toxicity and improving therapeutic window.

The present disclosure provides anti-CD38 IgG class antibody having improved ability to be manufactured at higher yields compared to the parent antibody having the original wild type sequence. The present disclosure provides a mutated antibody light chain that reduces cleavage heterogeneity for improved production of a homogeneous population of antibody light chains.

The application provides a pig getah virus positive serum and a preparation method and application, and belongs to the technical field of animal virology. The application provides a preparation method of a pig getah virus positive serum, wherein a CDCD pig is used as a host, neutralizing antibody titer obtained through multiple immunization of high-concentration antigen is greater than or equal to 1:512; the serum does not have cytotoxicity affecting cell culture; the CDCD pig is a pig free from maternal antibody interference, which is obtained through caesarean section, isolated feeding and artificial feeding; the positive serum does not detect pig pseudorabies virus, swine fever virus, porcine circovirus type 2, pig foot-and-mouth disease virus, bovine viral diarrhea virus, porcine infectious gastroenteritis virus, porcine epidemic diarrhea virus, porcine rotavirus, porcine parvovirus, porcine Japanese encephalitis virus antibody, and has the characteristics of high titer and no cytotoxicity.

The present invention provides a humanized anti-Bb factor antibody, a composition containing the antibody, a method for producing the antibody, and a method for using the antibody, for treating complement-mediated diseases or disorders. [Solution] A humanized anti-Bb factor antibody is provided that combines only a specific heavy chain variable region (VH) and light chain variable region (VL) to bind to Bb factor with an acceptable binding affinity. The humanized anti-Bb factor antibody of this disclosure has a binding affinity of no more than twice that of the parent antibody.

This application provides isolated antibodies, and antigen-binding fragments thereof that specifically bind chemokine receptor 4 (CXCR4). These CXCR4 antibodies, or antigen-binding fragments thereof, have a high affinity for CXCR4, function to effectively block SDF-1 binding to CXCR4, thereby inhibiting forskolin stimulated cAMP with low nM IC50, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., in a human), and can be used to treat CXCR4-associated disorders while avoiding the adverse side effects associated with the current CXCR4 antagonist therapies.

The invention belongs to the technical field of biology, and discloses an influenza HA protein recombinant turkey herpesvirus strain, the preservation number of the recombinant turkey herpesvirus strain is CGMCC No.46642, and the recombinant turkey herpesvirus strain is preserved in China General Microbiological Culture Collection Center; the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation date is July 23, 2025. The recombinant turkey herpesvirus has the characteristics that: 1, the recombinant turkey herpesvirus has good safety and immunogenicity, can induce strong body fluid and cellular immune response, can realize early immunization through intraembryonic or 1-day-old inoculation, and reduces interference of maternal antibodies; and 2, the HA gene of the H7 subtype AIV and the virus HA gene of the H5 subtype AIV are inserted into the virus strain, the two genes are independently screened by the applicant, and after being loaded on an HVT vector, the HA gene and the virus HA gene can show relatively comprehensive protection aiming at the corresponding subtype. Meanwhile, the invention also provides application and a vaccine of the recombinant herpesvirus of turkeys.